Fig. 1From: Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?Therapeutic scenario for patients with advanced non-squamous ‘undruggable’ NSCLC (EGFR wild type, ALK and ROS1 non-rearranged, PD-L1 < 50%)Back to article page